FDA Extends Shelf Life of COVID-19 Treatment for Hospitalized Adults
The Food and Drug Administration last week
extended to 30 months the shelf life for certain lots of Gohibic (vilobelimab),
authorized for emergency use to treat COVID-19 in certain hospitalized adults. The six-month extension applies to all retained product held in accordance with storage conditions detailed in the
fact sheet for health care providers.